INEYE THERAPEUTICS, S.A. has just secured a new investment round totaling €600,000, with continued support from Portugal Ventures and the entry of Insight Venture as a co-investor. This follow-on investment of €250,000 from Portugal Ventures follows an initial investment of €100,000 made in 2023 under the INNOV-ID Call program.
This new round marks a decisive step forward in the development of the InEye® technology, focused on the treatment of dry eye syndrome.
“INEYE THERAPEUTICS is an inspiring example of how knowledge generated within our universities can be transformed into innovation with global impact. This new investment round reflects our confidence in the team and in the potential of the technology, which addresses a real need in the treatment of ocular diseases. We remain committed to supporting disruptive solutions made in Portugal that advance science and healthcare.”
— Pedro Mello Breyner, Executive Board Member, Portugal Ventures
“At Insight Venture, we actively seek projects with a strong scientific foundation and transformative potential. INEYE THERAPEUTICS represents exactly that — a combination of talent, innovation, and strategic vision in biotechnology. This co-investment with Portugal Ventures reinforces our commitment to fostering the national health and innovation ecosystem.”
— Mónica Cameira de Mendonça, President, Insight Venture
